Introduction: Middle-aged women are often faced with the dilemma of whether to use hormone therapy or not. Until recently, advertisements, as well as, very often, the scientific literature, advocated the use of hormone therapy. The aim of this study was to determine women's use of hormone therapy and its correlation with age, self-rated health status and lifestyle factors.
Materials And Methods: An anonymous postal questionnaire was sent to 5,300 women over 44 years of age. The public health insurance office in Roskilde County picked 100 women at random for each of the 53 general practitioners who entered the survey in 1998. 72% of the women answered the questionnaire. The data set was statistically analysed using multiple linear logistic regression, taking account of the fact that the data had been obtained through general practitioners.
Results: 35% (95% CI 32-38) of the women 50-55 years of age were currently using or had formerly used hormone therapy. As many as 51% (95% CI 46-56) of the women 60-64 years of age were currently using or had formerly used hormone therapy. More than 50% of the women who were using hormone therapy had done so for more than 10 years. The group of women 45-59 years of age with the worst self-rated health status had odds of 5.1 (95% CI 3.0-8.6) of current or former use of hormone therapy as compared with the women with the highest self-rated health status. The odds of current use of hormone therapy were comparable at 2.7 (95% CI 1.5-4.7) for the women with the lowest self-rated health status as compared with the women with the highest self-rated health status. There was a positive correlation between the use of hormone therapy and physical exercise, tobacco use, former use of oral contraceptives and examination of cholesterol level.
Discussion: The percentage of women over 44 years of age who currently use or have formerly used hormone therapy in our study is comparable with the results of Danish surveys since 1983. Women 45-59 years of age who use hormone therapy do not have the same high level of self-rated health as that of women aged 45-59 years who have not used hormone therapy.
Download full-text PDF |
Source |
---|
Periodontol 2000
January 2025
ADA Forsyth Institute, Cambridge, Massachusetts, USA.
Tooth movement is a complex process involving the vascularization of the tissues, remodeling of the bone cells, and periodontal ligament fibroblasts under the hormonal and neuronal regulation mechanisms in response to mechanical force application. Therefore, it will inevitably impact periodontal tissues. Prolonged treatment can lead to adverse effects on teeth and periodontal tissues, prompting the development of various methods to reduce the length of orthodontic treatment.
View Article and Find Full Text PDFCureus
December 2024
Medical Oncology, Jawaharlal Nehru Medical College, Wardha, IND.
Gynecomastia, the abnormal enlargement of male breast tissue, is a rare side effect associated with dasatinib. This drug is used in the treatment of chronic myeloid leukemia (CML). We present a case of dasatinib-induced gynecomastia in a 52-year-old gentleman with CML who developed bilateral breast enlargement and tenderness after approximately four months of dasatinib treatment.
View Article and Find Full Text PDFCureus
December 2024
Department of Obstetrics and Gynecology, Shiga University of Medical Science, Ostu, JPN.
Familial Mediterranean fever (FMF) is an autoinflammatory disease characterized by periodic fever, serositis, and arthritis. In women, FMF attacks can sometimes be triggered by the menstrual cycle. Once diagnosed, prophylactic treatment with colchicine is generally recommended.
View Article and Find Full Text PDFFront Immunol
January 2025
Department of Clinical Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Objectives: The feasibility of corticosteroid withdrawal (CW) for Takayasu arteritis (TAK) remains uncertain. Two autoantibodies (Abs) are identified against endothelial protein C receptor (EPCR) and scavenger receptor class B type 1 (SR-BI) in TAK, determining its three subgroups. This study aimed to evaluate CW using tocilizumab (TCZ) and its association with the Ab profile.
View Article and Find Full Text PDFDifferences/disorders of sex development (DSDs) are a diverse group of congenital conditions that result in disagreement between an individual's sex chromosomes, gonads, and/or anatomical sex. The 46, XY DSD group is vast and includes various conditions caused by genetic variants, hormonal imbalances, or abnormal sensitivity to testicular hormones, leading to varying degrees of under-virilization. A 19-year-old phenotypically normal female from Kakamega, Kenya, presented with primary amenorrhea.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!